Publications

Manuscripts

    • Murray BE, Jezek A; The Antibacterial Resistance Leadership Group: First Steps. Clin Infect Dis. 2017; 64 (suppl_1): S1-S2. doi: 10.1093/cid/ciw8.
    • Chambers HF, Cross HR, et al. The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress. Clin Infect Dis. 2017; 64 (suppl_1): S3-S7. doi: 10.1093/cid/ciw824.
    • Cross HR, Harris A, et al. Transforming Concepts Into Clinical Trials and Creating a Multisite Network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017; 64 (suppl_1): S8-S12. doi: 10.1093/cid/ciw825.
    • Manca C, Hill C, et al. Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017; 64 (suppl_1): S13-S17. doi: 10.1093/cid/ciw826.
    • Huvane J, Komarow L, et al. Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017; 64 (suppl_1): S18-S23. doi: 10.1093/cid/ciw827.
    • Doernberg SB, Lodise TP, et al. Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017; 64 (suppl_1): S24-S29. doi: 10.1093/cid/ciw828.
    • Doi Y, Bonomo RA, et al. Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017; 64 (suppl_1): S30-S35. doi: 10.1093/cid/ciw829.
    • Anderson DJ, Jenkins TC, et al. The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017; 64 (suppl_1): S36-S40. doi: 10.1093/cid/ciw830.
    • Tsalik EL, Petzold E, et al. Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group. Clin Infect Dis. 2017; 64 (suppl_1): S41-S47. doi: 10.1093/cid/ciw831.
    • Evans SR, Hujer AM, et al. Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics (RMDs) to Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. PRIMERS III. J Clin Microbiol. 2016 Dec 28;55(1):134-144. doi: 10.1128/JCM.01524-16.
    • Rojas LJ, Salim M, et al. Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality. Clin Infect. Epub 2016 Dec 11.
    • Patel R, Tsalik EL, et al. Viewpoint: MASTERMIND – Bringing Microbial Diagnostics to the Clinic. Clin Infect. Epub 2016 Dec 7.
    • Banerjee R, Ozenci V, et al. Viewpoint: Individualized Approaches Are Needed for Optimized Blood Cultures. Clin Infect Dis. 2016 Nov 15.
    • Evans SR, Harris AD. Methods and Issues in Studies of CRE. Virulence. 2016 Jul 28; doi; 10.1080/21505594.2016.1213473; Epub 2016 July 28.
    • Evans S, Kreiswirth B, et al. Reply to Lesho and Clifford: “In the Eye of a Storm”: The Goal of Rapid Molecular Diagnostics in PRIMERS I and II. Clin Infect Dis. 2016 May 25. pii: ciw336.
    • Evans S, Pennello G, et al. Benefit-Risk Evaluation for Diagnostics: a   Framework (BED-FRAME).Clin Infect Dis. 2016 July; 63 (6): 812-817. doi: 10.1093/cid/ciw329. Epub 2016 May 18.
    • Goodman KE, Lessler J, et al. A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrum β-Lactamase–Producing Organism. Clin Infect Dis. 2016 July; doi: 10.1093/cid/ciw425. Epub 2016 June 28.
    • Hauck C, Cober E, et al.  Spectrum of Excess Mortality due to Carbapenem-Resistant Klebsiella pneumoniae Infections. Clin Microbiol Infect. 2016 Jun:22(6):513-9.
    • Wright MS, lovleva A, et al. Genome Dynamics of Multidrug-resistant Acinetobacter baumannii during Infection and Treatment. Genome Med. 2016 Mar 3;8(1):26. doi: 10.1186/s13073-016-0279-y.
    • Thaden JT, Keller AE, et al. Pseudomonas aeruginosa Bacteremic Patients Exhibit Non-Protective Antibody Titers against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide. J Infect Dis. 2016 Feb 15. 213(4):640-8.
    • Messina JA, Thaden JT, et al. Impact of Bacterial and Human Genetic Variation on Staphylococcus aureus Infections. PLoS Pathogens. 2016 Jan 14;12(1):e1005330.
    • Tsalik EL, Henau R, et al. Host Gene Expression Classifiers Diagnose Acute Respiratory Illness Etiology. Sci Transl Med. 2016 Jan 20;8(322):322ra11.
    • Messina JA, Cober E, et al. Hospital Readmissions in Patients with Carbapenem-Resistant Klebsiella 1 pneumonia. Infect Control Hosp Epidemiol. 2015 Dec 21:1-8.
    • Evans SR, Follmann D.Fundamentals and Innovation in Antibiotic Trials. Stat Biopharm Res. 2015;7(4):331-336.
    • Ericson JE, Popoola VO, et al. Burden of Invasive Staphylococcus aureus Infections in Hospitalized Infants. JAMA Pediatr. 2015;169(12):1105-1111
    • Banerjee R, Teng C, et al. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. 2015 Oct 1;61(7):1071-80. doi: 10.1093/cid/civ447. Epub 2015 Jul 20
    • Choe H, Narayanan AS, et al. Immunomodulatory Peptide IDR-1018 Decreases Implant Infection and Preserves Osseointegration. Clin Orthop Relat Res. 2015 Sep 30;473(9):2898-907.
    • Evans S, Hujer AM, et al.  Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. Clin Infect Dis. 2015 Sep 25. pii: civ837. [Epub ahead of print]
    • Khatri A, Naeger MN, et al. Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015 Aug 31;59(8):4375-8. doi: 10.1128/AAC.00553-15.
    • Bergin SP, Thaden J, et al. Neonatal Escherichia coli Bloodstream Infections: Clinical Outcomes and Impact of Initial Antibiotic Therapy. Pediatr Infect Dis J. 2015 Aug 31;34(9):933-936.
    • van Duin, Cober E, et al. Residence in Skilled Nursing Facilities is associated with Tigecycline Nonsusceptibility in Carbapenem-Resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2015 Aug;36(8):942-8.
    • Uno H, Wittes J, et al.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Ann Intern Med. 2015 Jul 21;163(2):127-34.
    • Banerjee R, Teng C, et al. Randomized Trial of Rapid Multiplex PCR-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. Epub (preprint) 2015 July 20.
    • Evans SR, Rubin D, et al. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Days of Antibiotic Risk (RADAR). Clin Infect Dis. 2015 Jun 25. pii: civ495. Epub 2015 Jun 25.
    • Ando Y, Hamasaki T, et al. Sample size considerations in clinical trials when comparing two interventions using multiple co-primary binary relative risk contrasts. Stat Biopharm Res. 2015 Jun 24;7(2):81-94.
    • Messina JA, Fowler VG Jr, et al. Oritavancin for Acute Bacterial Skin and Skin Structure Infections. Expert Opin Pharmacother. 2015 May 17;16(7):1091-8.
    • Evans S, Hujer AM, et al. Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. Clin Infect Dis. 2015 Apr;34(4):371-5
    • Hamasaki T, Asakura K, et al. Group-sequential Strategies in Clinical Trials with Multiple Co-primary Outcomes. Stat Biopharm. 2015 Apr;2015;7(1):36-54.
    • Ericson JE, Thaden J, et al. No Survival Benefit with Empirical Vancomycin Therapy for Coagulase-negative Staphylococcal Bloodstream Infections in Infants.  Pediatr Infect Dis J.  2015 Apr;34(4):371-5.
    • van Duin, Cober E, et al. Impact of Therapy and Strain Type on Outcomes in Urinary Tract Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae. Antimicrob Chemother. 2015 Apr 1;70(4):1203-11.
    • Spellberg B, Barlett J, et al. Novel Approaches Are Needed to Develop Tomorrow’s Antibacterial Therapies.  Am J Respir Crit Care Med. 2015 Jan 15;191(2):135-40.
    • Tamma PD, Han JH, et al. Carbapenem Therapy is Associated with Improved Survival Compared With Piperacillin-Tazobactam for Patients With Extended-Spectrum β-Lactamase Bacteremia. Clin Infect Dis. 2015 Jan 13. pii: civ003. Epub ahead of print.
    • Wright MS, Suzuki Y, et al. Genomic and Transcriptomic Analyses of Colistin-Resistant Clinical Isolates of Klebsiella pneumoniae Reveal Multiple Pathways of Resistance. Antimicrob Agents Chemother. 2015 Jan;59(1):536-43. doi: 10.1128/AAC.04037-14. Epub 2014 Nov 10.
    • van Duin D, Cober E, Richter SS, et al. Tigecycline Therapy for Carbapenem-Resistant Klebsiella pneumoniae (CRKP) Bacteriuria Leads to Tigecycline Resistance. Clin Microbiol Infect. 2014 Dec; 20(12):O1117-20. doi: 10.1111/1469-0691.12714. [Epub ahead of print].
    • Vazquez Melendez EL, Farrell JJ, et al. Culture Negative Empyema in A Critically Ill Child: An Opportunity for Rapid Molecular Diagnostics. BMC Anesthesiol. 2014 Nov 22;14:107. doi: 10.1186/1471-2253-14-107. eCollection 2014.
    • Perez F, Adachi J, Bonomo RA. Antibiotic-Resistant Gram-Negative Bacterial Infections in Patients with Cancer. Clin Infect Dis. 2014 Nov 15;59 Suppl 5:S335-9. doi: 10.1093/cid/ciu612.
    • Stafford KA, Boutin M, Evans SR, et al.Difficulties in demonstrating superiority of an antibiotic for multidrug-resistant bacteria in nonrandomized studies. Clin Infect Dis. 2014 Oct 15;59(8):1142-7. doi: 10.1093/cid/ciu486. Epub 2014 Jun 30.
    • Holland TL, Arnold C, Fowler VG Jr. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA. 2014 Oct 1;312(13):1330-41.doi: 10.1001/jama.2014.9743.
    • Perez F, Hujer AM, et al. Extensively Drug-Resistant Pseudomonas Aeruginosa Isolates Containing blaVIM-2 and Elements of Salmonella Genomic Island 2: A New Genetic Resistance Determinant in Northeast Ohio. Antimicrob Agents Chemother. 2014 Oct;58(10):5929-35. doi: 10.1128/AAC.02372-14. Epub 2014 Jul 28
    • David MZ, Daum RS, et al. Staphylococcus aureus Bacteremia at Five U.S. Academic Medical Centers, 2008-2011: Significant Geographic Variation in Community-Onset Infections. Clin Infect Dis. 2014 Sep15;59(6):798-807 doi: 10.1093/cid/ciu410 Epub 2014 May 30.
    • Spellberg B, Gibert DN. The Future of Antibiotics and Resistance: A Tribute to a Career of Leadership by John Bartlett. Clin Infect Dis. 2014 Sep 15;59 Suppl 2:S71-5. doi: 10.1093/cid/ciu392.
    • Nagalingam S, Lisgaris M, et al. Identification of Occult Fusobacterium Nucleatum Central Nervous System Infection By Use of PCR-Electrospray Ionization Mass Spectrometry. J Clin Microbiol. 2014 Sep;52(9):3462-4. doi: 10.1128/JCM.01082-14. Epub 2014 Jun 25.
    • Wright MS, Perez F, Brinkac L, et al. Population Structure of KPC-producing Klebsiella pneumoniae from Midwestern US Hospitals. Antimicrob Agents Chemother. 2014 Aug;58(8):4961-5. doi: 10.1128/AAC.00125-14. Epub 2014 Jun 9.
    • van Duin D, Perez F, Rudin SD, et al. Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional Network. Antimicrob Agents Chemother. 2014 Jul;58(7):4035-4041. Epub 2014 May 5.
    • Asakura K, Hamasaki T, Sugimoto T, et al. Sample size determination in group-sequential clinical trials with two co-primary endpoints. Stat Med. 2014 Jul 30;33(17):2897-913. doi: 10.1002/sim.6154. Epub 2014 Mar 27.
    • Spellberg B. The Future of Antibiotics. Crit Care. 2014 Jun 27;18(3):228. doi: 10.1186/cc13948.
    • Ramirez MS, Xie G, Johnson S, et al. Genome Sequences of Two Carbapenemase-Resistant Klebsiella pneumoniae ST258 Isolates. Genome Announc. 2014 Jun 19;2(3). pii: e00558-14. doi: 10.1128/genomeA.00558-14.
    • Chambers HF, Barlett JG, Bonomo RA, et al. Antibacterial resistance leadership group: open for business. Clin Infect Dis. 2014 Jun;58(11):1571-6. doi: 10.1093/cid/ciu132. Epub 2014 Mar 6.
    • Tugal D, Lynch M, et al. Multi-Drug-Resistant Klebsiella pneumoniae Pancreatitis: A New Challenge in a Serious Surgical Infection. Surg Infect (Larchmt). 2014 May 21 [Epub ahead of print].
    • Perez F, Bonomo RA. Vaccines for Acinetobacter baumannii: Thinking “Out of the Box”. Vaccine. 2014 May 7;32(22):2537-9.
    • Fowler VG Jr, Proctor RA. Where does a Staphylococcus aureus vaccine stand? Clin Microbiol Infect. 2014 May;20 Suppl 5:66-75. doi: 10.1111/1469-0691.12570.
    • Spellberg B. Antibiotic Judo: Working Gently with Prescriber Psychology to Overcome Inappropriate Use. JAMA Intern Med. 2014 Mar;174(3):432-3. doi: 10.1001/jamainternmed.2013.14019

Abstracts

    • Rojas LJ, Cober E, et al. Molecular Analysis of Colistin Resistance among Klebsielle pneumoniae Producing KPC (Kp-KPC): Heterogeneity of Genetic Mechanisms. Presented at ID Week October 2016.
    • Nguyen MH, Shields RK, et al. Impact of Rectal Colonization with Highly Drug-resistant Enterobacteriaceae on Post-transplant Infections: The Carbapenem Resistant Enterobacteriaceae Carriage in Solid Organ Transplant (CREST) Study. Presented at ID Week October 2016.
    • Henig O, van Duin, et at. Epidemiology and Management of Skin and Soft Tissue Infection (SSTI) due to Carbapenem Resistant Enterobacteriaceae: A Report from The Consortium on Resistance against Carbapenems in Klebsiella. pneumoniae (CRaCKle). Presented at ID Week October 2016.
    • Evans SR, Tran T, et al. Choosing Ceftazidime/Avibactam and Ceftolozane/Tazobactam as Empiric Therapies against Pseudomonas aeruginosa (Pa) using Rapid Molecular Diagnostics (RMDs): PRIMERS IV. Presented at ID Week October 2016.
    • Doernberg S, Gouskova N, et al. BAC DOOR: A Clinician Ranking Exercise for Better S. aureus Bacteremia Trial Design. Presented at ID Week October 2016.
    • Anderson DJ, Watson S, et al. Feasibility Assessment of Stewardship Interventions in Community Hospitals: a Multicenter, 3-Stage Cluster-Randomized Historically Controlled Crossover Trial. Presented at ID Week September 2016.
    • Van Duin D, Cober E, et al. Colistin versus Ceftazidime/Avibactam in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Presented at ECCMID April 2016.
    • Holland T, Mikita S, et al. Streamlining Antibacterial Drug Development Programs to Address Unmet Medical Need: Patient and Provider Attitudes on a Modified Benefit-Risk Calculus. Presented at ATS May 2016.
    • Jacobs MR, Hujer AM, et al. Antimicrobial Susceptibility of Carbapenem-Susceptible and -Resistant Acinetobacter baumannii (Ab): PRIMERS-III, part 1. Presented at ID Week October 2015.
    • Salim M, Perez, F et al. Colistin Resistance in Patients with Carbapenem-resistant Klebsiella pneumoniae is Associated with Increased Mortality. Presented at ID Week October 2015.
    • Evans S, Jiang H, et al. Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics (RMDs) to Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. PRIMERS-III. Presented at ID Week October 2015.
    • Evans S, Jiang H, et al. Benefit:Risk Evaluation in Diagnostics: An Example Comparing Two Rapid Molecular Diagnostics Testing Imipemem Susceptibility in Acinetobacter spp. Presented at ID Week October 2015.
    • Van Duin D, Perez F et al. The Spectrum of Attributable Mortality due to Carbapenem-Resistant Klebsiella pneumoniae (CRKp). Presented at ICAAC September 2015 and ID Week October 2015.
    • Van Duin D, Perez F et al. The Movement of Carbapenem-Resistant Klebsiella pneumoniae (CRKP) among Healthcare Facilities: A Network Analysis. Presented at ID Week October 2015.
    • Domitrovic TN, Hujer AM, et al. Is It Time to Identify Acinetobacter spp. by Molecular Methods Only? Presented at ID Week October 2015.
    • Hill C, Manca C, et al. A Novel Research Resource: Virtual Bacteria Strain Repository. Presented at ICAAC September 2015.
    • Banerjee R, Teng C, et al. Randomized Trial of Blood Culture Pathogen Identification Using the FilmArray Blood Culture ID Panel (BCID) vs. Standard Culture Techniques: Impact on Antimicrobial Use and Outcomes. Presented at ICAAC September 2014.
    • Adams MD, Wright M, Marshall S, et al. Genetic Analysis of Colistin Resistance Using RNA-seq in Klebsiella pneumonia. Presented at ICAAC September 2014.
    • Khatri A, Naeger Murphy N, Wiest P, et al. Pyelonephritis In pregnancy caused by carbapenem-resistant Enterobacteriaceae (CRE): an emerging community infection? Presented at ICAAC September 2014.
    • Messina J, Cober E, Richter SS, et al. Use of Tigecycline in Patients with Carbapenem-resistant Klebsiella pneumoniae (CRKP) is Associated with Increased Risk for Readmissions with CRKP. Presented at ID Week October 2014.
    • Perez F, Rudin SD, Cober E et al. Temporal trends among ST258 Klebsiella pneumoniae strains harboring blaKPC (KPC-Kp) in the Great Lakes region: insights from molecular surveillance. Presented at ICAAC September 2014.
    • Ramirez M, Johnson S, Xie G, et al. Whole-genome Sequence Comparison of Two Carbapenem-resistant ST258 Klebsiella pneumoniae Strains Reveals Potential Markers for Clinical and Epidemiologic Identification in the HHZ Region. Presented at ICAAC September 2014.
    • Thaden JT, Ericson JE, Cross H, et al. Survival Benefit of Empirical Vancomycin Therapy for Staphylococcus aureus Bloodstream Infections in Infants. Presented at ICAAC September 2014.
    • Van Duin D, Cober E, Richter SS, et al. Community Origin and Mortality in Pneumonia Caused by Carbapenem-Resistant Klebsiella pneumoniae. Presented at ID Week October 2014.
    • Van Duin D, Perez F, Ruding SD, et al. Impact of ST258 Klebsiella pneumoniae harboring KPC in the Great Lakes region: insights from the Consortium on Resistance against Carbapenems in K. pneumonia (CRaCKle). Presented at ICAAC September 2014.
    • Hujer AM, Evans S, Jiang H, et al. Can Rapid Molecular Diagnostics Assist in the Choice of b-Lactam Antibiotics? An Analysis of Data from PRIMERS-II of the Antibiotic Resistance Leadership Group (ARLG). Presented October 2014, ID Week 2014.
    • Ericson JE, Hornik CP, Thaden J, et al. Empirical Vancomycin Therapy for Coagulase-Negative Staphylococcal Sepsis in Infants. Presented at PAS  May 2014.
    • Hujer AM, Evans SR, Jiang H, et al. Can Rapid Molecular Diagnostics Assist in the Choice of Beta-Lactam Antibiotics? An Analysis of Data from PRIMERS-I. Presented at ECCMID May 2014.
    • Banerjee R, Teng C, et al. Clinical and Economic Impact of Rapid Identification and Susceptibility Testing of Pathogens Growing in Blood Culture Bottles. Presented at Translational Science April 2014.
    • Hujer AM, Hujer KM, Jacobs M, et al. Using Molecular Diagnostics to Decipher the Genetic Basis of Antibiotic Resistance in Clinical Isolates of Gram-Negative Bacteria. [Abstract 42292]. Poster presentation at ID Week 2013. October 2013.